Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | SQLE | Q14534 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2347077 | 1.00 | KMT2A (0.68) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL352059 | 1.00 | KMT2A (0.68) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL30531903 | 0.98 | KMT2A (0.73) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL2495183 | 0.98 | KMT2A (0.73) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| Hydrochloric Acid SCHEMBL27745841 | 0.98 | KMT2A (0.65) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL30531904 | 0.98 | KMT2A (0.73) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL2495184 | 0.98 | KMT2A (0.73) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL21260659 | 0.98 | KMT2A (0.73) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL20624673 | 0.98 | KMT2A (0.73) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL11892318 | 0.98 | KMT2A (0.73) | KMT2AMEN1CYP3A4ALOX15SQLE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025089950-A1 | PROCESS FOR REMOVING CO2 FROM GAS | CARBONORO TECHNOLOGY B.V. (NL) | 2025-05-01 | — | — | WO | claimed |
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-10 | — | — | US | claimed |
| CN-118895124-A | Single-particle explosive fluorescent scintillating carbon dot and preparation method and application thereof | 西安石油大学 | 2024-11-05 | — | — | CN | claimed |
| WO-2024183010-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | 中国科学院过程工程研究所 | 2024-09-12 | — | — | WO | claimed |
| CN-117479964-A | Tissue-selective single-component mRNA delivery vector and delivery system | 中国科学院过程工程研究所 | 2024-01-30 | — | — | CN | claimed |
| CN-113387786-B | Safener for protecting cereal from herbicide | 河南省农业科学院植物保护研究所 | 2023-08-01 | — | — | CN | claimed |
| CN-108366597-B | Substance mixture | 西姆莱斯有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-113387786-A | A safener for protecting grains from herbicide | 河南省农业科学院植物保护研究所 | 2021-09-14 | — | — | CN | claimed |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | claimed |
| EP-2616056-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | Neuroquest Inc. (CA) | 2013-07-24 | — | — | EP | claimed |
| CN-101111240-A | Isolation of n-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of n-butylbenzenesulfonamide and benzenesulfonamide derivatives for the treatment of benign prostate hyperp | LOHMANN THERAPIE SYST LTS (DE) | 2008-01-23 | — | — | CN | claimed |
| EP-1142859-B1 | Process for producing optically active 3,7-dimethyl-6-octenol and process for producing intermediate therefore | TAKASAGO PERFUMERY CO LTD (JP) | 2006-12-13 | — | — | EP | claimed |
| US-6489522-B2 | ORGANOLEPTIC; FROM ALKYLAMINE AND ISOPRENE; CATALYTIC ISOMERIZATION, HEATING | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-12-03 | — | — | US | claimed |
| US-6486353-B2 | SUBJECTING MIXTURE OF ALKYLAMINE AND ISOPRENE TO TELOMERIZATION AT 80-100 DEGREES C.IN THE PRESENCE OF AN ALKYLLITHIUM AND/OR PHENYLLITHIUM CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-11-26 | — | — | US | claimed |
| US-20020128525-A1 | Process for producing optically active 3,7-dimethyl-6-octenol and process for producing intermediate therefor | TAKASAGO INTERNATIONAL CORPORATION | 2002-09-12 | — | — | US | claimed |
| US-20020004620-A1 | Process for producing optically active 3, 7-dimethyl-6-octenol and process for producing intermediate therefor | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-10 | — | — | US | claimed |
| EP-1142859-A2 | Process for producing optically active 3,7-dimethyl-6-octenol and process for producing intermediate therefor | Takasago International Corporation (JP) | 2001-10-10 | — | — | EP | claimed |
| US-4266087-A | Process for preparing a myrcenol, cis-ocimenol mixture substantially free of trans-ocimenol | GIVAUDAN CORPORATION (US) | 1981-05-05 | — | — | US | claimed |
| US-4186148-A | Process for producing 3,7-dimethyl-2,6-octadienylamine derivatives | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 1980-01-29 | — | — | US | claimed |
| US-4107219-A | OXIDIZING UNSATURATED AMINE, THERMAL REARRANGEMENT TO FORM UNSATURATED HYDROXYLAMINE, HYDROGENATION | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1978-08-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | SLC43A1, LNPEP, TLR3 | KMT2A 2917/4885MEN1 4368/4885CYP3A4 3631/4885 |
| US-20020128525-A1 | Process for producing optically active 3,7-dimethyl-6-octenol and process for producing intermediate therefor | NOTUM, CYP51A1, SOAT2 | KMT2A 2881/4885MEN1 1751/4885CYP3A4 49/4885 |
| US-20020004620-A1 | Process for producing optically active 3, 7-dimethyl-6-octenol and process for producing intermediate therefor | NOTUM, CYP51A1, SOAT1 | KMT2A 2833/4885MEN1 1625/4885CYP3A4 49/4885 |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | PMP22, PTGES, GGPS1 | KMT2A 3842/4885MEN1 2728/4885CYP3A4 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.